Markets
EW

Analysts Forecast 15% Upside For The Holdings of XLV

An image of multiple stacks of coins
Credit: Shutterstock photo

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Health Care Select Sector SPDR Fund ETF (Symbol: XLV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $80.43 per unit.

With XLV trading at a recent price near $69.75 per unit, that means that analysts see 15.31% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of XLV's underlying holdings with notable upside to their analyst target prices are AbbVie Inc. (Symbol: ABBV), Regeneron Pharmaceuticals, Inc. (Symbol: REGN), and Edwards Lifesciences Corp (Symbol: EW). Although ABBV has traded at a recent price of $60.00/share, the average analyst target is 23.75% higher at $74.25/share. Similarly, REGN has 23.73% upside from the recent share price of $346.50 if the average analyst target price of $428.73/share is reached, and analysts on average are expecting EW to reach a target price of $120.19/share, which is 23.52% above the recent price of $97.30. Below is a twelve month price history chart comparing the stock performance of ABBV, REGN, and EW:

ABBV, REGN, and EW Relative Performance Chart

Combined, ABBV, REGN, and EW represent 5.49% of the Health Care Select Sector SPDR Fund ETF. Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
Health Care Select Sector SPDR Fund ETF XLV $69.75 $80.43 15.31%
AbbVie Inc. ABBV $60.00 $74.25 23.75%
Regeneron Pharmaceuticals, Inc. REGN $346.50 $428.73 23.73%
Edwards Lifesciences Corp EW $97.30 $120.19 23.52%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

10 ETFs With Most Upside To Analyst Targets »

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

EW REGN XLV ABBV

Other Topics

ETFs

Latest Markets Videos

    BNK Invest

    BNK Invest Inc. provides investment services and information. BNK Invest owns and operates a market news family of websites including DividendChannel, ETFChannel, StockOptionsChannel, and others, which make up an investor community featuring stock message boards, ratings, research, and strategies. BNK Invest caters to investing firms and individual investors internationally.

    Learn More